CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.…
CVRx to Participate at the Piper Sandler 38th Annual Healthcare Conference
CVRx (NASDAQ: CVRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 223 employees.
The shares were at 0.5010 USD on 20 November 2026, down 94.8% over 52 weeks. Its 52-week range is 0.4972 USD to 10.28 USD, and it trades at the bottom of that range.
Its market capitalisation is 14.27M USD.
CVRx reports return on equity of -135.6%, an operating margin of -81.9% and revenue down 5.8% year over year.
Its debt exceeds its cash by 639.00K USD, a debt-to-equity ratio of 1.28. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Hold; their mean price target of 1.650 USD is 229.3% above the current price. The next earnings report is expected on 11 February 2027.